Fig. 2

Combination therapy blocked metastasis of TNBC and extended mice survival. A Illustration of optimized protocol for dual therapy in 4T1 tumors. B Representative images showing lung metastasis. C Statistical analysis of the number of lung metastasis. D The body weight of BALB/c mice bearing 4T1 tumors upon different treatments (n = 6 mice per group). E Dot plot showed the expression levels of immune suppressive genes in different subtypes of T cells in the lung metastases of 4T1 models, where dot size and color represent percentage of gene expression (pct. exp) and the averaged scaled expression (avg. exp. scale) value, respectively. F Illustration of optimized protocol for triple therapy in AT3 tumors. G-J Evaluation the efficacy of optimized triple therapy in AT3 tumors. Tumor growth curves (G); lung BLI (H) (43 days post tumor inoculation); body weight (I); Kaplan-Meier survival curves of C57BL/6J mice bearing AT3 tumors (J). (G, I and J) Control, n = 15, Anti-PD-1, n = 15, SH100 + OLA, n = 15, SH100 + OLA + anti-PD-1, n = 9. (H) Control, n = 5, Anti-PD-1, n = 6, SH100 + OLA, n = 6, SH100 + OLA + anti-PD-1, n = 6. In (G and I), the symbol “^*” denotes the difference between Control and SH100 + OLA + anti-PD-1. The symbol “^#” denotes the difference between Control and SH100 + OLA. K Rechallenge scheme for survived mice in AT3 tumors. L Whole-body BLI analysis of tumor burden 14 days after AT3 cells reinoculation. M Interferon-γ (IFN-γ) ELISPOT analysis of splenocytes harvested 14 days after AT3 reinoculation. P values were obtained by unpaired two-tailed t test (C, G, H, I and M), n.s., non-significant, ^{*, #}P < 0.05; ^{**, ##}P < 0.01; ^{***, ###}P < 0.001, or Mantel-Cox test (J), n.s., non-significant, ^***P < 0.001. Data were shown as the means ± SEM